Therapeutic strategies for metabolic diseases: small-molecule diacylglycerol acyltrasferase (DGAT) inhibitors = 대사질환 치료제로서의 DGAT 저해제 리뷰

Cited 30 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorR Naik-
dc.contributor.authorB W Obiang-Obounou-
dc.contributor.authorM Kim-
dc.contributor.authorY Choi-
dc.contributor.authorHyun Sun Lee-
dc.contributor.authorK Lee-
dc.date.accessioned2017-04-19T09:57:33Z-
dc.date.available2017-04-19T09:57:33Z-
dc.date.issued2014-
dc.identifier.issn1860-7187-
dc.identifier.uri10.1002/cmdc.201402069ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/12234-
dc.description.abstractMetabolic diseases such as atherogenic dyslipidemia, hepatic steatosis, obesity, and type II diabetes are emerging as major global health problems. Acyl-CoA:diacylglycerol acyltransferase (DGAT) is responsible for catalyzing the final reaction in the glycerol phosphate pathway of triglycerol synthesis. It has two isoforms, DGAT-1 and DGAT-2, which are widely expressed and present in white adipose tissue. DGAT-1 is most highly expressed in the small intestine, whereas DGAT-2 is primarily expressed in the liver. Therefore, the selective inhibition of DGAT-1 has become an attractive target with growing potential for the treatment of obesity and type II diabetes. Furthermore, DGAT-2 has been suggested as a new target for the treatment of DGAT-2-related liver diseases including hepatic steatosis, hepatic injury, and fibrosis. In view the discovery of drugs that target DGAT, herein we attempt to provide insight into the scope and further reasons for optimization of DGAT inhibitors.-
dc.publisherWiley-
dc.titleTherapeutic strategies for metabolic diseases: small-molecule diacylglycerol acyltrasferase (DGAT) inhibitors = 대사질환 치료제로서의 DGAT 저해제 리뷰-
dc.title.alternativeTherapeutic strategies for metabolic diseases: small-molecule diacylglycerol acyltrasferase (DGAT) inhibitors-
dc.typeArticle-
dc.citation.titleChemmedchem-
dc.citation.number0-
dc.citation.endPage2424-
dc.citation.startPage2410-
dc.citation.volume9-
dc.contributor.affiliatedAuthorHyun Sun Lee-
dc.contributor.alternativeNameNaik-
dc.contributor.alternativeNameObiang-Obounou-
dc.contributor.alternativeName김민경-
dc.contributor.alternativeName최용석-
dc.contributor.alternativeName이현선-
dc.contributor.alternativeName이경-
dc.identifier.bibliographicCitationChemmedchem, vol. 9, pp. 2410-2424-
dc.identifier.doi10.1002/cmdc.201402069-
dc.subject.keywordDGAT-
dc.subject.keyworddiacylglycerol acyltransferase-
dc.subject.keywordmetabolic disorders-
dc.subject.keywordsmall-molecule inhibitors-
dc.subject.keywordtriacylglycerides-
dc.subject.localDGAT-
dc.subject.localdiacylglycerol acyltransferase-
dc.subject.localdiacylglycerol acyltansferase (DGAT)-
dc.subject.localDiacylglycerol acyltransferase-
dc.subject.localDiacylglycerol acyltransferase (DGAT)-
dc.subject.localmetabolic disorders-
dc.subject.localmetabolic disorder-
dc.subject.localMetabolic disorders-
dc.subject.localSmall-molecule inhibitor-
dc.subject.localsmall-molecule inhibitors-
dc.subject.localtriacylglycerides-
dc.description.journalClassY-
Appears in Collections:
Ochang Branch Institute > Natural Product Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.